Medicare Enrolled
Dr. Ravin Rupani, M.D.
Internal Medicine · Montebello, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rupani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rupani?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rupani
Dr. Ravin Rupani is an internal medicine specialist in Montebello, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Rupani performed 1,557 Medicare services across 597 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rupani received a total of $25,161 from 93 pharmaceutical and/or device companies across 1234 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rupani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 21% volume in CA
$25,161 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,557
Medicare services
Top 21% in CA for internal medicine
597
Unique beneficiaries
$74
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~86 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
329 | $101 | $276 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
201 | $12 | $30 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
200 | $100 | $221 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
192 | $62 | $192 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
142 | $67 | $193 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
91 | $8 | $13 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
77 | $67 | $142 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
75 | $89 | $140 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
67 | $150 | $369 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
63 | $58 | $147 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
47 | $148 | $376 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
32 | $1 | $2 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
24 | $90 | $276 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
17 | $146 | $366 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.0% high complexity
15.0% medium
81.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$25,161
Total received (2018-2024)
Avg $3,594/year across 7 years
Top 5% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
93
Companies
1,234
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$24,401 (97.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$760 (3.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,770
2023
$4,979
2022
$4,416
2021
$3,927
2020
$3,128
2019
$2,622
2018
$2,318
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$430
Celgene Corporation
$315
PFIZER INC.
$261
Merck Sharp & Dohme LLC
$223
Eisai Inc.
$190
Incyte Corporation
$190
Gilead Sciences, Inc.
$175
AstraZeneca Pharmaceuticals LP
$158
GlaxoSmithKline, LLC.
$149
E.R. Squibb & Sons, L.L.C.
$146
Takeda Pharmaceuticals U.S.A., Inc.
$136
Genentech USA, Inc.
$114
Daiichi Sankyo Inc.
$107
Astellas Pharma US Inc
$100
ABBVIE INC.
$89
Janssen Biotech, Inc.
$74
SpringWorks Therapeutics, Inc.
$68
BeiGene USA, Inc.
$67
EMD Serono, Inc.
$61
Alexion Pharmaceuticals, Inc.
$58
Karyopharm Therapeutics Inc.
$56
Bayer Healthcare Pharmaceuticals Inc.
$55
Exelixis Inc.
$55
Boehringer Ingelheim Pharmaceuticals, Inc.
$54
GENZYME CORPORATION
$51
Rigel Pharmaceuticals, Inc.
$37
Immunocore Limited
$34
Genmab U.S., Inc.
$33
Aveo Pharmaceuticals, Inc.
$31
PharmaEssentia USA Corporation
$31
PUMA BIOTECHNOLOGY, INC.
$27
Deciphera Pharmaceuticals Inc.
$26
MorphoSys, US Inc.
$24
ARRAY BIOPHARMA INC
$23
Stemline Therapeutics Inc.
$23
Lilly USA, LLC
$22
Regeneron Healthcare Solutions, Inc.
$21
ImmunoGen, Inc.
$21
SOBI, INC
$19
Mirati Therapeutics, Inc.
$18
Top 3 companies account for 26.7% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$2,597
Novartis Pharmaceuticals Corporation
$2,160
E.R. Squibb & Sons, L.L.C.
$1,349
PFIZER INC.
$1,267
Incyte Corporation
$1,254
Astellas Pharma US Inc
$982
AstraZeneca Pharmaceuticals LP
$889
Janssen Biotech, Inc.
$836
Takeda Pharmaceuticals U.S.A., Inc.
$761
GlaxoSmithKline, LLC.
$699
Genentech USA, Inc.
$605
GENZYME CORPORATION
$583
Merck Sharp & Dohme LLC
$577
Seagen Inc.
$501
Pharmacyclics LLC, An AbbVie Company
$498
Amgen Inc.
$497
Gilead Sciences, Inc.
$454
Exelixis Inc.
$439
Lilly USA, LLC
$434
Eisai Inc.
$431
Bayer HealthCare Pharmaceuticals Inc.
$428
Boehringer Ingelheim Pharmaceuticals, Inc.
$358
Daiichi Sankyo Inc.
$346
Merck Sharp & Dohme Corporation
$335
Kite Pharma, Inc.
$309
Karyopharm Therapeutics Inc.
$294
Rigel Pharmaceuticals, Inc.
$259
Puma Biotechnology, Inc.
$246
EMD Serono, Inc.
$239
Bayer Healthcare Pharmaceuticals Inc.
$224
Seattle Genetics, Inc.
$219
Taiho Oncology, Inc.
$188
Regeneron Healthcare Solutions, Inc.
$173
Alexion Pharmaceuticals, Inc.
$164
ARRAY BIOPHARMA INC
$159
BeiGene USA, Inc.
$153
TerSera Therapeutics LLC
$151
EISAI INC.
$139
PharmaEssentia USA Corporation
$124
Teva Pharmaceuticals USA, Inc.
$114
Blueprint Medicines Corporation
$102
PUMA BIOTECHNOLOGY, INC.
$100
Genmab U.S., Inc.
$99
Pharmacyclics LLC, an AbbVie Company
$98
Dendreon Pharmaceuticals LLC
$93
ABBVIE INC.
$89
INSYS Therapeutics Inc
$88
Secura Bio, Inc.
$88
Mirati Therapeutics, Inc.
$87
TAIHO ONCOLOGY, INC.
$81
MorphoSys, US Inc.
$79
Epizyme, Inc.,
$76
Myovant Sciences Inc.
$73
Dova Pharmaceuticals
$71
Spectrum Pharmaceuticals Inc.
$71
Verastem, Inc.
$70
SpringWorks Therapeutics, Inc.
$68
Deciphera Pharmaceuticals Inc.
$67
G1 Therapeutics, Inc.
$67
Sobi, Inc
$65
SOBI, INC
$64
Adaptive Biotechnologies Corporation
$52
MEDIVATION FIELD SOLUTIONS LLC
$52
AbbVie Inc.
$51
Sumitomo Pharma America, Inc.
$50
JAZZ PHARMACEUTICALS INC.
$49
Clovis Oncology, Inc.
$48
RECORDATI_RARE_DISEASES_INC.
$45
EUSA Pharma (US) LLC
$44
Global Blood Therapeutics, Inc.
$43
GE HEALTHCARE
$42
Array BioPharma Inc.
$41
Stemline Therapeutics Inc.
$41
Agios Pharmaceuticals, Inc.
$37
Immunocore Limited
$34
Emmaus Medical, Inc.
$34
Aveo Pharmaceuticals, Inc.
$31
Foundation Medicine, Inc.
$31
Janssen Scientific Affairs, LLC
$29
ADC Therapeutics America, Inc.
$29
Sun Pharmaceutical Industries Inc.
$26
Acrotech Biopharma LLC
$22
AbbVie, Inc.
$22
Shire North American Group Inc
$22
ImmunoGen, Inc.
$21
Jazz Pharmaceuticals Inc.
$21
AVEO Pharmaceuticals, Inc.
$20
Mylan Institutional Inc.
$17
TESARO, Inc.
$17
Partner Therapeutics, Inc.
$14
Advanced Accelerator Applications
$14
Sirtex Medical Inc
$14
GE HealthCare
$13
Top 3 companies account for 24.3% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Endari · Enhertu · Epkinly · FARYDAK · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAVRETO · GILOTRIF · GRANIX · HEMADY · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INQOVI · INREBIC · Idhifa · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ogivri · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · PROVENGE · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · RUXIENCE · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SUTENT · SYLVANT · SYNDROS · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 5% for internal medicine in CA.
Geographic Context
Internal medicine physicians within 10 mi
5,500
Per 100K population
55.8
County median income
$87,760
Nearest hospital
ADVENTIST HEALTH WHITE MEMORIAL MONTEBELLO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rupani is a clinical cardiology specialist, with above-average Medicare volume (top 21% in CA), with low-engagement industry engagement in the top 5% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rupani experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Rupani performed 329 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rupani receive payments from pharmaceutical companies?
Yes. Dr. Rupani received a total of $25,161 from 93 companies across 1,234 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rupani's costs compare to other internal medicine physicians in Montebello?
Dr. Rupani's average Medicare payment per service is $74. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rupani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Montebello
Browse internal medicine physicians in Montebello ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology